Compare Nucor Corporation (NUE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Nucor Corporation trades at $248.12 (market cap $55.84B), while Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B). The key difference: Nucor Corporation is far larger — about 26.1× Recursion Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NUE | RXRX | |
|---|---|---|
Market Cap | $55.84B | $2.14B |
Volume | 848,835 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $6.79 |
52-Week Low | $131.78 | $2.84 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $60.25B | $1.66B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.44, down 1.84% on the day, with a neutral technical signal and mixed earnings history including a Q2 2026 beat. Revenue and net income have shown volatility, with 2025 revenue at $32.49B and net income at $1.74B, while analyst consensus is a 'Buy' with a $266.88 price target. Recent news highlights steel sector dynamics and Nucor's Q3 2026 earnings guidance.
The outlook for NUE is cautiously optimistic, supported by analyst bullishness and projected earnings growth, but risks include competitive pressures from new steel capacity and cyclical demand fluctuations. Investment opportunity lies in its solid fundamentals and dividend history, though investors should weigh margin pressures and market volatility.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
